instruments as a result of capital increase during the first quarter and proceeds from disposition of assets in the following quarter in 2018. Profit and Loss Results In 2018, the Company recorded net loss of

recognition from The Ritz-Carlton Residences, Bangkok (“RCR”) which is a part of MahaNakhon project. As a result, the Company was able to repay loans during the period. Apart from that, the capital increase

was able to repay loans during the period. Apart from that, the capital increase from the investment of Apollo had resulted in the ability to terminate the outstanding debts to financial institutions as

paid of 810 million Baht, a decrease of 166 million Baht or 17% as compared to 2017. The decrease in finance cost was due to repayments in various of debt instruments as a result of capital increase

operating system setting. In addition, MAT was in the process of the capital increase and propose to partly repay Baht 200,000. During this time, the Legal Department has been monitoring the progress with MAT

million Baht, decreasing by 31% as compared to the same period last year of 260 million Baht. The decrease in the finance costs was from a result of loan repayment regarding the capital increase in Q1 2018

and Allocation of the Newly Issued Ordinary Shares and the Newly Issued Convertible Debenture of Hydrotek Public Company Limited to the Specific Investor (Private Placement) 3. Capital Increase Report

capital increase of Baht 55 million. Please be informed accordingly. Sincerely yours, Miss Suwarin Konthong Executive Vice President of Account and Finance DOD Biotech Public Company Limited

expenses in Q1, 2018 came from the payment to financial consulting, expenses from the extraordinary general shareholder’s meeting and extra cost from specific capital increase in January 2018. 5. Management

net profit of Baht 223.32 million, ordinary share premium of Baht 939.87 million and new share issuance for capital increase of Baht 55 million, net of interim dividend payment of Baht 226.00 million